{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:54:13Z","timestamp":1791564853708,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SS2019013"],"award-info":[{"award-number":["SS2019013"]}],"id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejphar.2026.179308","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:13:00Z","timestamp":1788361980000},"page":"179308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel cyclic-peptide antagonist of TIM-3 for cancer immunotherapy by reinvigorating exhausted T-cell activity"],"prefix":"10.1016","volume":"1034","author":[{"given":"Ying","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhou","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-0958","authenticated-orcid":false,"given":"Yimin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7764","key":"10.1016\/j.ejphar.2026.179308_bib1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.22.02270","article-title":"Phase I study of single-agent anti-programmed Death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ejphar.2026.179308_bib3","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179308_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.immuni.2007.01.016","article-title":"T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface","volume":"26","author":"Cao","year":"2007","journal-title":"Immunity"},{"issue":"40","key":"10.1016\/j.ejphar.2026.179308_bib5","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by a D-Peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"7749","key":"10.1016\/j.ejphar.2026.179308_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179308_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179308_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4049\/jimmunol.1302663","article-title":"T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases","volume":"192","author":"Clayton","year":"2014","journal-title":"J. Immunol."},{"issue":"13","key":"10.1016\/j.ejphar.2026.179308_bib9","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib clinical trial of sabatolimab, an Anti-TIM-3 antibody, alone and in combination with spartalizumab, an Anti-PD-1 antibody, in advanced solid tumors","volume":"27","author":"Curigliano","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"issue":"15","key":"10.1016\/j.ejphar.2026.179308_bib11","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2021.04.019","article-title":"The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake","volume":"54","author":"De Mingo Pulido","year":"2021","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib13","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"Dekruyff","year":"2010","journal-title":"J. Immunol."},{"issue":"15_Suppl. l","key":"10.1016\/j.ejphar.2026.179308_bib14","article-title":"Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: a phase I\/II trial in progress","volume":"38","author":"Desai","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"93","key":"10.1016\/j.ejphar.2026.179308_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci. Immunol."},{"issue":"7865","key":"10.1016\/j.ejphar.2026.179308_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41586-021-03626-9","article-title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation","volume":"595","author":"Dixon","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179308_bib17","series-title":"Immuno-Oncology: Cellular and Translational Approaches","first-page":"89","article-title":"A human in vitro T cell exhaustion model for assessing immuno-oncology therapies","author":"Dunsford","year":"2020"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179308_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.36401\/JIPO-23-4","article-title":"T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review","volume":"7","author":"Duong","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.ejphar.2026.179308_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fphys.2011.00004","article-title":"A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks","volume":"2","author":"Eissing","year":"2011","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2026.179308_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-016-0146-9","article-title":"Cancer immunotherapy trials: leading a paradigm shift in drug development","volume":"4","author":"Emens","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"18","key":"10.1016\/j.ejphar.2026.179308_bib21","doi-asserted-by":"crossref","first-page":"12002","DOI":"10.1021\/acs.jmedchem.2c00539","article-title":"Discovery of cyclic peptide inhibitors targeting PD-L1 for cancer immunotherapy","volume":"65","author":"Fetse","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179308_bib23","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/psp4.12636","article-title":"A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions","volume":"10","author":"Frechen","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179308_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-12-396962-0.00004-5","article-title":"Peptide discovery using bacterial display and flow cytometry","volume":"503","author":"Getz","year":"2012","journal-title":"Methods Enzymol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179308_bib26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes De Morais","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejphar.2026.179308_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119984","article-title":"Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression","volume":"247","author":"Gurung","year":"2020","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179308_bib28","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"8_Suppl. l","key":"10.1016\/j.ejphar.2026.179308_bib29","article-title":"A phase Ia\/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): interim safety, efficacy, and pharmacokinetic findings in advanced cancers","volume":"37","author":"Harding","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179308_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"7534","key":"10.1016\/j.ejphar.2026.179308_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1163462","article-title":"Role of IL-2 in cancer immunotherapy","volume":"5","author":"Jiang","year":"2016","journal-title":"Oncoimmunology"},{"issue":"7873","key":"10.1016\/j.ejphar.2026.179308_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179308_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/abt\/tbaa022","article-title":"A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy","volume":"3","author":"Kuang","year":"2020","journal-title":"Antibody Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib36","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179308_bib37","doi-asserted-by":"crossref","first-page":"6253","DOI":"10.1016\/j.apsb.2025.10.014","article-title":"Site-specific PEGylation of proteins: insights into structural and functional changes","volume":"15","author":"Ma","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"722","key":"10.1016\/j.ejphar.2026.179308_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg6752","article-title":"Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models","volume":"15","author":"Ma","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2026.179308_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.saa.2017.05.023","article-title":"Alteration of human serum albumin binding properties induced by modifications: a review","volume":"188","author":"Maci\u0105\u017cek-Jurczyk","year":"2018","journal-title":"Spectrochim. Acta Mol. Biomol. Spectrosc."},{"issue":"44","key":"10.1016\/j.ejphar.2026.179308_bib40","doi-asserted-by":"crossref","first-page":"13732","DOI":"10.1002\/anie.201707707","article-title":"Bioactive macrocyclic inhibitors of the PD-1\/PD-L1 immune checkpoint","volume":"56","author":"Magiera-Mularz","year":"2017","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.179308_bib41","article-title":"Safety and preliminary efficacy of sabestomig (AZD7789), an Anti-PD-1 and Anti-TIM-3 bispecific antibody, in patients with relapsed or refractory classical hodgkin lymphoma previously treated with Anti-PD-(L)1 therapy","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"issue":"7378","key":"10.1016\/j.ejphar.2026.179308_bib42","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179308_bib43","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","article-title":"Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study","volume":"119","author":"Mo","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"6871","key":"10.1016\/j.ejphar.2026.179308_bib44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"10124","key":"10.1016\/j.ejphar.2026.179308_bib45","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179308_bib46","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2026.179308_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176144","article-title":"Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress","volume":"960","author":"Qin","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1110\/ps.051897806","article-title":"Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands","volume":"15","author":"Rice","year":"2006","journal-title":"Protein Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179308_bib50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1385690","article-title":"Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy","volume":"7","author":"Sabatos-Peyton","year":"2018","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179308_bib51","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib52","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.immuni.2007.11.008","article-title":"Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds","volume":"27","author":"Santiago","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib53","article-title":"A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events","volume":"1","author":"Sasikumar","year":"2013","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179308_bib55","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179308_bib56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ymthe.2021.11.015","article-title":"Spatial distribution and functional analysis define the action pathway of Tim-3\/Tim-3 ligands in tumor development","volume":"30","author":"Wang","year":"2022","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179308_bib57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179308_bib58","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2026.179308_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115583","article-title":"Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy","volume":"212","author":"Wu","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib60","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.apsb.2020.01.005","article-title":"A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses","volume":"10","author":"Zhai","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179308_bib61","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1744921","article-title":"Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody","volume":"9","author":"Zhang","year":"2020","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179308_bib62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179308_bib63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-16-2379","article-title":"Intrinsic resistance of solid tumors to immune checkpoint blockade therapy","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179308_bib64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2017.07.004","article-title":"Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy","volume":"181","author":"Zhao","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179308_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-020-04167-0","article-title":"The biologically functional identification of a novel TIM3-binding peptide P26 in vitro and in vivo","volume":"86","author":"Zhong","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179308_bib66","first-page":"1","article-title":"TIM-3 and its regulatory role in immune responses","volume":"350","author":"Zhu","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ejphar.2026.179308_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbpa.2017.02.006","article-title":"Cyclic peptide therapeutics: past, present and future","volume":"38","author":"Zorzi","year":"2017","journal-title":"Curr. Opin. Chem. Biol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:17:30Z","timestamp":1791562650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926007909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"alternative-id":["S0014299926007909"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179308","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel cyclic-peptide antagonist of TIM-3 for cancer immunotherapy by reinvigorating exhausted T-cell activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179308"}}